Pneumonia is the leading cause of death among neutropenic cancer patients, particularly those with acute leukaemia. Even with empiric therapy, case fatality rates of neutropenic pneumonias remain unacceptably high. However, recent advances in the management of neutropenic pneumonia offer hope for improved outcomes in the cancer setting. This review summarizes recent literature regarding the clinical presentation, microbiologic trends, diagnostic advances and therapeutic recommendations for cancer-related neutropenic pneumonia.
INTRODUCTION
Worldwide, pneumonia profoundly affects all populations [1] [2] [3] [4] . However, the impact of pneumonia on cancer populations is uniquely severe, accounting for more morbidity and mortality than any other infectious complication [5] [6] [7] [8] [9] [10] [11] [12] [13] . This review addresses the epidemiology, pathophysiology, microbiology, diagnostics and therapeutics relevant to clinical care of pneumonia in neutropenic cancer patients, with particular emphasis on recent guidelines.
EPIDEMIOLOGY
Lower respiratory tract infections are strikingly common among cancer patients. Reports indicate that 13-31% of leukaemia patients receiving chemotherapy [8] [9] [10] [12] [13] [14] and up to 80% of haematopoietic stem cell transplant (HSCT) recipients will experience at least one episode of pneumonia [15, 16] . The mortality attributable to pneumonia in these populations is very high with case fatality rates in leukaemia patients ranging from 25 to 80% [11, 17, 18] , and the case fatality rate in HSCT recipients is as high as 90% [8] [9] [10] [12] [13] [14] [18] [19] [20] [21] [22] [23] . cancer patients promote exposure to nosocomial and drug-resistant pathogens.
Among the risks for cancer-related pneumonia, neutropenia is the most prominent. Neutrophils are sensitive to alkylating agents and nucleoside analogues, resulting in dose-dependent reductions in the absolute neutrophil count. Severe neutropenia, defined as a count less than 500/ml, is associated with severe lung infections caused by bacterial and fungal organisms [24] . The rapidity of onset, duration, severity and underlying physiologic process all impact susceptibility to neutropenic pneumonia [7, 20, [25] [26] [27] [28] [29] [30] . Moreover, impairments of neutrophil phagocytosis and chemotaxis follow common cancer-related insults such as radiation, corticosteroids, hypovolemia, acidosis and hyperglycemia [31] . Thus, functional neutropenia can also contribute to cancer-related pneumonia risk.
MICROBIOLOGY AND THE SPECTRUM OF PATHOGENS
The spectrum of pathogens to which neutropenic patients are susceptible is staggeringly broad (see Table 1 ). It is, therefore, helpful to consider the site of acquisition, because this impacts the spectrum of pathogens and their antimicrobial resistance patterns and therefore determines optimal treatment strategy.
Community-acquired organisms
Genuine community-acquired pneumonia (CAP), defined as development of pneumonia in patients who have not been hospitalized or resided in a nursing home for at least 14 days prior to the onset of symptoms, and who do not meet criteria for other risk groups [32] [33] [34] , is relatively uncommon among cancer patients, owing to their frequent healthcare exposures [35 & ]. This is particularly true among neutropenic patients, as this typically reflects recent chemotherapy. Nonetheless, outpatient neutropenic individuals routinely encounter community pathogens, so physicians must consider
KEY POINTS
Pneumonia in the cancer patient accounts for more morbidity and mortality than any other complication.
Initial broad-spectrum antibacterial coverage including resistant Gram negatives and MRSA is warranted in high-risk neutropenic cancer patients, with antifungals for those that have persistent fevers or risk factors.
Serum and BAL galactomannan testing is now more widely available for clinical use and may be beneficial in select patients with neutropenic fever and suspicion of pneumonia.
Host-directed therapies that enhance innate epithelial immunity and that reconstitute the immune system are undergoing clinical investigation. Table 1 . Pathogens of special concern in neutropenic pneumonia Although community-acquired organisms cause pneumonia in neutropenic patients, it is crucial to recall that neutropenic patients do not respond to pathogens similarly to non-neutropenic individuals. What might be an easily cleared inoculum for an immunocompetent patient may cause life-threatening pneumonia in the setting of neutropenia. Guidelines for CAP management were developed for patients without immune dysfunction [32, 46] . Consequently, clinical scoring strategies to direct management of CAP, such as the Pneumonia Severity Index (PSI) and the CURB-65, may underestimate the severity of illness in the neutropenic population and should be used with caution [35 & ].
Nosocomial bacterial pathogens
By virtue of their healthcare interactions, most neutropenic outpatients are typically best categorized as having healthcare-associated pneumonia (HCAP), rather than CAP. Formally, HCAP encompasses pneumonia that develops in outpatients who have been hospitalized for at least 2 days in the prior 90 days, received treatment in a hospital or haemodialysis clinic, resided in long-term care facilities, received intravenous antibiotics, chemotherapy or wound care in the prior 30 days [47 && ]. This definition is contrasted with hospital-acquired pneumonia (HAP), wherein pneumonia develops at least 48 h after hospital admission, or ventilator-associated pneumonia, which develops more than 48-72 h after endotracheal intubation [47 && ]. The spectrum of pathogens causing HCAP substantially overlaps that of late-onset HAP or VAP [47 && ,48] , and the available guidelines for management of these nosocomial infections overlap [47 && ]. The bacterial causes of nosocomial pneumonias in cancer patients without recent antibiotic exposure include S. pneumoniae, S. aureus and H. influenzae. In those with cancer patients with neutropenia, additional pathogens to be considered are the Gram-negative enteric organisms, including Pseudomonas spp., Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, S. maltophilia, Citrobacter spp., Serratia marcescens, Acinetobacter baumannii-complex and Proteus spp. [15,41 & ,43,44,49-52] . Unfortunately, the rise in Gram-negative neutropenic respiratory infections has also yielded a corresponding increase in extended spectrum beta-lactamaseproducing Enterobacteriaceae. Mortality rates associated with drug-resistant P. aeruginosa and methicillinresistant S. aureus (MRSA) are disproportionately higher than those caused by other nosocomial bacterial pathogens [53] . Finally, sporadic outbreaks of Legionella pneumophila and Norcardia spp. have occasionally been reported by various transplant centres and should be considered depending on the context [54] [55] [56] .
Fungi
Although bacterial pathogens cause documented neutropenic pneumonias about twice as often as fungi [13, 27] , invasive pulmonary mycoses are associated with significant morbidity and mortality. Aspergillus is the most common fungal pneumonia in neutropenic patients, with Aspergillus fumigatus being the most frequently culture of this genus, although A. flavus, A. niger and amphotericin B resistant A. terreus have also emerged as important pathogens [57,58 && ]. Risk factors for aspergillus pneumonia include both duration (>1 week) and severity (<100 cells/ml) of neutropenia [59] [60] [61] . Non-Aspergillus moulds such as Fusarium spp., Pseudaalesheria boydii, Scedosporium spp. and the dematiaceous moulds that are often not susceptible to conventional antifungal agents are also described in this population [62, 63] .
Widespread use of fluconazole prophylaxis appears to have induced a decline in pneumonias caused by endemic mycoses, such as Histoplasma capsulatum, Blastomycetes dermatitidis and Coccidioides immitis. However, neutropenic pneumonias caused by zygomycetes (mainly mucorales) have increased in recent years, corresponding with increased use of voriconazole and declining use of amphotericin B (to which these organisms are more often susceptible) [63] .
Although Pneumocystis jiroveci pneumonia is typically seen in patients with CD4 þ cell depletion, this organism must also be considered as a cause of neutropenic pneumonia, particularly in patients with severe hypoxemia [64, 65] . Because of the effectiveness of trimethoprim-sulfamethoxazole prophylaxis during the neutropenic period after HSCT, most pneumocystis in HSCT patients is now seen among sulpha-allergic patients receiving less effective prophylaxis [66] .
Viruses
The incidence of cytomegalovirus (CMV) infection has declined in recent years due to aggressive prophylaxis and preemptive therapy, but active infections continue to cause severe morbidity, especially among seronegative HSCT recipients [67] [68] [69] . Detection of CMV viremia or antigenemia strongly suggests active disease, whereas detection of CMV in lower respiratory tract secretions may reflect viral shedding without active infection. Consequently, the observation of cytopathic changes can help in diagnosing CMV pneumonia. Respiratory syncytial virus (RSV) pneumonia is relatively uncommon in the neutropenic adult population, but is associated with very high mortality rates [40, 70] . Other less common causes of viral lower respiratory tract infections include varicella-zoster and human herpes virus 6.
Mycobacteria
Mycobacterium tuberculosis is a rare cause of neutropenic pneumonia, typically seen among foreignborn individuals receiving cancer care in nonendemic regions [71] . Most cases are reactivation episodes of latent infections rather than de-novo infections. Conversely, nontuberculous mycobacterial lower respiratory tract infections are widely reported among neutropenic patients [72] .
Polymicrobial
Polymicrobial isolates are common among patients with neutropenic pneumonia [73] . Because of the frequency with which multiple organisms are identified on respiratory samples, recent guidelines support the use of semi-quantitative or quantitative cultures in patients with suspected HCAP, HAP and VAP [47 && ]. An unfortunate consequence of frequent polymicrobial infections is that a positive test for one pathogen does not necessarily allow withholding of empiric therapies for other pathogens.
DIAGNOSTICS
Evaluation of neutropenic cancer patients with suspected pneumonia requires careful clinical and microbiologic assessment, supplemented by selected molecular testing for particular pathogens.
Clinical assessment
The classical clinical signs of pneumonia in most populations include new pulmonary infiltrates, leukocytosis, fever and purulent secretions. However, due to disordered host inflammatory responses in the neutropenic cancer patient, these clinical and radiographic hallmarks may be unapparent [25, 40, 41 & ,47 && ,62]. Thus, early computed tomographic (CT) scanning is warranted for neutropenic patients with unanticipated clinical deterioration, unexplained fevers or questionable infiltrates on conventional imaging [40,41 & ,62 ]. However, the differential diagnosis of pulmonary infiltrates is expansive and includes noninfectious mimics such as leukemic infiltrates, drug toxicity and hydrostatic pulmonary oedema. Thus, although infection remains the most frequent cause of these radiographic abnormalities in neutropenic patients [13, 21, 22, 27, 45, 74] , the potential diagnoses are numerous and the challenge is to identify those patients who are most likely to benefit from further investigations in addition to empiric antimicrobial therapy [21, 22, 45, 74] .
Microbiologic assessment
Neutropenic pneumonia is most reliably diagnosed when a likely pathogen is recovered from a typically sterile site or when a noncommensal organism is isolated from respiratory secretions. Although practice patterns vary widely [75] , bronchoscopy with bronchoalveolar lavage (BAL) is the diagnostic tool of choice for obtaining lower respiratory samples from neutropenic cancer patients [8, 76] . BAL is well tolerated for most cancer patients [8] , although traditional culture methods yield a definite pathogen in only 25-51% of cases [8, 19, [76] [77] [78] [79] . The diagnostic benefit of BAL is likely greatest when performed early, particularly if it can be done prior to the initiation of antimicrobial therapy [8, 76, 80] . However, therapy should not be delayed so that a BAL can be done, as the detrimental effects of delays in treatment outweigh the modest gains recognized by having improved BAL sensitivity. When feasible, transbronchial biopsies (TBBx) may reveal angioinvasion by microbes (e.g. Aspergillus spp.); however, culturing TBBx material has not been proved superior to BAL and TBBx carries a higher risk of complications such that it is often precluded in neutropenic patients because of concurrent thrombocytopenia.
Interpretation of BAL culture data can be challenging, due to frequent colonization of the upper airway with nonpathogenic microorganisms [41 & ]. Autopsy studies suggest that in the presence of sufficiently severe immunosuppression, many organisms that are usually considered as colonizers can cause significant disease. Thus, the clinician must carefully assess each patient to determine the appropriateness of responding to positive culture results. Conversely, sterile cultures do not exclude infection, particularly in the setting of prior antibiotic utilization [40,41 & ]. These diagnostic challenges have promoted the use of modern molecular techniques to enhance the sensitivity of BAL and to facilitate the discrimination of bona fide pathogens from irrelevant commensals. Such techniques include PCR testing and antigen detection methods [41 & ,45,81] .
Molecular testing for galactomannan as a test for invasive aspergillosis
Early diagnosis of invasive aspergillosis remains problematic, because microbiologic proof is often not possible [82, 83] . Invasive aspergillosis may be suggested by CT findings that may include nodular infiltrates, with or without cavitation, sometimes with patchy or segmental consolidation [84 & ]. Peribronchial infiltrates and tree-in-bud patterns can also be seen, and radiographic findings vary with host factors and the degree of immunosuppression. As highlighted in Fig. 1 , although CT imaging may be suggestive of invasive aspergillosis, the range of potential radiographic patterns overlaps with other causes of pneumonia. Thus, CT imaging is not sufficient to make a definitive diagnosis.
Because sputum and BAL cultures have limited sensitivity [85] [86] [87] , there has been increasing interest in molecular tests and immunoassays for diagnosing invasive aspergillosis. The best characterized, clinically available assay is the Platelia galactomannan assay, which has been approved by the U.S. Food and Drug Administration (FDA) for use on serum and BAL.
Galactomannan is a heat-stable polysaccharide found in the cell wall of Aspergillus spp. Immunoassays have been developed to test for galactomannan in serum and BAL to aid clinical diagnosis [88] [89] [90] . The FDA-approved galactomannan enzyme immunoassay (EIA) presents results as a ratio of the test sample optical density relative to a provided control optical density; optical density ratios at least 0.5 (the 'optical index') are considered positive. Once thought specific for Aspergillus, it is now clear that the galactofuranose side chain epitopes targeted by the EIA may react with Fusarium spp., Penicillium spp. and Histoplasma capsulatum [91] [92] [93] . False-positive serum galactomannan tests have been reported in patients receiving certain formulations of piperacillin-tazobactam [94] ; however, subsequent studies suggest that current preparations of piperacillin-tazobactam do not generate cross-reactivity [95] .
Several strategies of galactomannan testing have been evaluated, including testing BAL and serum in patients with suspected disease and screening serum of high-risk patients without current evidence of disease. These strategies are reviewed below. Because cultures are frequently negative and tissue usually cannot be obtained, the reference standard for many of these studies has therefore been the EORTC/MSG consensus group standards, which categorize cases as none, possible, probable or proven [96, 97] .
Bronchoalveolar lavage galactomannan and serum testing in patients with suspected disease
A meta-analysis of 30 studies found that BAL galactomannan testing had a pooled sensitivity of 0.87 [95% confidence interval (95% CI) 0.79-0.92] and a pooled specificity of 0.89 (95% CI 0.85-0.92) [98] . The pooled likelihood ratio positive was 8.0 (95% CI 5.7-11.1) and the pooled likelihood ratio negative was 0.15 (95% CI 0.10-0.23). Sources of heterogeneity identified included differences in study design (cohort vs. case-control studies), study size, prior exposure to antifungals and neutropenia status.
In addition, the optical density ratios that were used to define positive galactomannan assays varied between studies, and this variation in threshold values had a moderate influence on heterogeneity. The optimal threshold value for defining positive results is an area of ongoing debate. In a retrospective study of 251 consecutive patients undergoing BAL galactomannan testing, a threshold of at least 0.8 had a sensitivity of 86.4% and a specificity of 90.7%, resulting in a positive predictive value (PPV) of 81% and a negative predictive value (NPV) of 93.6% [99] Adjusting the threshold to at least 3.0 resulted in a specificity of 100%, while lowering the threshold to less than 0.5 resulted in a very high sensitivity.
On balance, the available evidence for routine use of BAL galactomannan in neutropenic patients with pneumonia is inconclusive. A recent prospective observational cohort study of 568 patients with haematologic malignancies found that BAL galactomannan had a 50% sensitivity, 73% specificity, 16% PPV and 93% NPV for proven or probable invasive aspergillosis [84 & ]. With the posterior probability of disease ranging from 7 to 16%, it would be difficult to justify using galactomannan testing in this clinical context to decide on whether to start or stop antifungal therapy. However, depending on the threshold used and the pretest probability, BAL galactomannan might be useful in select cases.
Screening with galactomannan in patients without clinical evidence of disease
A meta-analysis identified 27 studies that evaluated surveillance with serum galactomannan testing for invasive aspergillosis in high-risk populations that used the EORTC/MSC consensus group or similar criteria as the reference standard [100] . The EORTC/ MSG consensus group categorize invasive aspergillosis cases as none, possible, probable or proven [96, 97] . Using proven invasive aspergillosis as the outcome, serum galactomannan had a pooled sensitivity of 0.71 (95% CI 0.68-0.74) and specificity of 0.89 (95% CI 0.88-0.90) [100] . If the outcome was proven or probable invasive aspergillosis, the pooled sensitivity was 0.61 (95% CI 0.59-0.63) and specificity was 0.93 (95% CI 0.92-0.94). Overall, these findings were consistent with moderate accuracy, despite significant study heterogeneity. Subgroup analysis revealed significant test characteristic variability depending on whether the outcome was proven vs. proven and probable, the patient population, the reference standard and the threshold values used for defining positive (Tables 2 and 3) . Galactomannan testing performed best in patients with haematologic malignancies and HSCT. Overall accuracy of galactomannan testing improved somewhat when a higher threshold was used to define positive results [100] .
On balance, the available evidence for the use of weekly or twice-weekly screening with galactomannan testing for high-risk patients remains inconclusive. There are no large, prospective, randomized trials using this screening strategy and it is not clear whether antifungal therapy could be withheld if the results were negative and clinical suspicion was high. Cost-effectiveness is also an issue. Important variables to consider include the underlying disease, the pretest probability of disease, what optical density threshold should be used, the relative magnitude of the consequences of false positive and false negative tests, and whether or not the information obtained will be actionable.
THERAPEUTIC STRATEGIES
The value of the information obtained from any of the above diagnostic tests is contingent on having effective therapeutic alternatives. Because of the broad range of potential pathogens, therapeutic strategies must integrate a variety of potential tools, including antibiotics, antifungals, antivirals and host-directed therapies.
Antibiotic therapies
Treatment should generally not be withheld while diagnostic interventions are undertaken. Delays in appropriate antimicrobial therapy increase the risk No consensus exists for the optimal time to first antibiotic dose, but one recent study suggests that neutropenic fever outcomes are better when antibiotics are delivered within 104 min of presentation [30] . Most clinicians would endorse the earliest possible dosing, with a possible exception when bronchoscopic evaluation is immediately available. In that case, it may be reasonable to hold empiric antibiotic therapy until completion of the brief procedure, potentially enhancing the diagnostic yield of the collected microbiologic cultures, but this delay should not be longer than 2 h. Antibiotics should not be held for hours or days in anticipation of bronchoscopy, as the harm from delaying therapy outweighs the benefits of improved test performance.
Initial antimicrobial therapy for febrile neutropenia in patients with pulmonary infiltrates cover the broad range of pathogens described above, with particular emphasis on antimicrobial activity against multidrug-resistant strains of S. aureus and P. aeruginosa [22,25,41 & ,102 & ]. Antibiotic selection should be based on culture data, pneumonia severity, local antibiotic sensitivity profiles and patient immune status [32] [33] [34] 46] . Empiric antibiotics for early HAP (i.e. within 7 days of admission) should include coverage of S. pneumoniae, MRSA, H. influenzae and Enterobacteriaceae. Initial regimens for patients with late HAP, HCAP or VAP should ensure enhanced coverage for multidrugresistant GNB [22,41 & 
,102
& ]. Secondary antibiotic selections for patients with refractory HAP, HCAP or VAP should be determined by institutional pathogen susceptibility profiles and on prior patient antimicrobial exposures [25,48,102 & ].
Early de-escalation of broad empiric therapy may be considered in patients who demonstrate prompt clinical response and in whom granulocyte recovery has occurred, especially if a susceptible pathogen has been identified [25] . De-escalation should be undertaken with caution in patients with poor clinical response to antimicrobial therapy, persistent neutropenia or ongoing immunosuppressive therapy [25,41 & ,102 & ].
ANTIFUNGALS
Early initiation of effective antifungal coverage is associated with improved outcomes in neutropenic pneumonia [103] . 
ANTIVIRALS
CMV and human herpes virus (HHV)-6 lower respiratory tract infections are treated with ganciclovir or foscarnet [41 & ,68,69,110,111] . The evidence on combining antiviral agents with intravenous immunoglobulin remains inconclusive [110, 111] . Even with aggressive therapy, mortality rates remain high with these viral infections [67] . Mortality rates among those with RSV pneumonia approach 80%, and initiation of treatment with aerosolized ribavirin and intravenous immunoglobulin initiated at the stage of upper respiratory infection is recommended to avoid progression [70] . Intravenous ribavirin has also been used successfully in patients with life-threatening human metapneumovirus disease [112] . Neuraminidase inhibitors, such as oseltamivir, are routinely prescribed for neutropenic patients with documented influenza infections, regardless of whether they have confirmed lung involvement [25] .
Host-directed therapies
Despite broad-spectrum antimicrobial strategies, mortality rates remain high in neutropenic patients. These antimicrobial failures arise, at least in part, from the continuing immune defects associated with the neutropenia. Consequently, a number of groups have investigated means by which the immune defects might be restored, allowing pathogen clearance. One focus is correction of the underlying neutropenia. Evidence supports the efficacy of colony-stimulating factors, but they are not generally recommended as a treatment for established infection [25] , although in the setting of invasive fungal infections reconstitution of the immune system appears essential for resolution [58 && ]. More recently, transfusion of donor granulocytes and administration of recombinant T H 1 cytokines have been studied, but this approach, although promising, is still investigational [113] [114] [115] . However, some authors argue that severely ill neutropenic patients may benefit from granulocyte transfusion [116] .
A novel alternative strategy to prevent and possibly treat pneumonias in the setting of neutropenia may be induction of innate antimicrobial responses from lung epithelial cells. Lung epithelial cells are long lived and relatively resistant to chemotherapy [117, 118] . In addition to their barrier function, recent investigations have demonstrated that these cells also possess the capacity to detect pathogens, to modulate local immune responses and to generate direct antibacterial responses through the production of antimicrobial peptides and reactive species [119] [120] [121] [122] [123] . Advances in the understanding of the molecular mechanisms involved in recognition and signal transduction have allowed development of inhaled therapeutics that induce protective innate immune responses from the lung epithelium in animals. In animal models of pneumonia, this provides protection from lethal pathogens even when there is concurrent neutropenic [124 & ,125-131] . One such treatment, known as PUL-042, is in clinical trials. Preclinical studies demonstrate that in animal models, PUL-042 protects against Gram-positive, Gram-negative, fungal and viral pathogen challenges. The real value of this approach is that it offers a new host-directed strategy for combatting infection in the neutropenic cancer patient that can be complementary to traditional antibacterial and antifungal therapeutics.
CONCLUSION
Neutropenic pneumonia remains a challenge for the clinician and a threat to the patient. The clinical approach requires integration of traditional microbiologic techniques as well as targeted molecular diagnostics. BAL and serum galactomannan are now more widely available and may be a useful adjunct in select patients, depending on the pretest probability of invasive aspergillosis. It remains uncertain how large an impact galactomannan testing can have, given that the posterior probabilities of disease are often not that different and that empiric treatment is often required. Therapeutic strategies still must rely on early recognition and initiation of broadspectrum antibacterial and antifungal therapy in appropriate patients. New host-directed therapies that help to reconstitute the immune system and others that stimulate epithelial innate immunity are under investigation in clinical trials. These may serve to supplement more traditional approaches in the future.
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